ORF Genetics is aninnovative plant biotechnology company and apioneer in developing and manufacturing high-quality recombinantproteins, such as growth factors, derived from barley plants. Founded in 2001, it has developed a unique technology, ORFEUS, which uses barley grain as a factory for recombinant protein production, providing a more efficient and safer method than other protein expression systems provide. The barley is grown in ORFs own high-tech, eco-friendly greenhouse, which is isolated in a black lava field on the Reykjanes Peninsula, Iceland, using the countries rich renewable energy resources.

ORFEUS has allowed ORF to develop a portfolio of growth factors, including human-like growth factors in the stem cell research market, as well as for its own successful skincare brand, BIOEFFECT. ORFs latest project, MESOkine, allows the production of animal-like growth factors in the cell cultured meat market.

The worlds meat industry is facing numerous challenges. Currently, 50% of the worlds vegetated land is being used for meat production and the demand formeat is rapidly growing. By 2050, when the worlds population will be close to 10 billion, food demand will have increased by approximately 56% and a shortfall in the supply of meat has been projected. Moreover, looming safety-, environmental-, and ethical concerns associated with the meat industry pose further challenges, providing momentum for disruption.

Cell cultured meat (CCM), even in its early stages, shows great merit over conventional meat and has the potential to disrupt the meat industry, helping the industry to overcome its challenges. An incredible amount of meat can be produced from a small sample of animal stem cells, without involving the slaughtering of animals. In comparison to conventionally produced meat, CCM uses 7-45% less energy, 90% less land, and 82-96% less water with 78-96% lower GHG emissions. Furthermore, CCM opens the prospect for land reforestation and restoration of endangered species.

To grow cell cultured meat, a tiny sample of stem cells is first collected from a muscle in the animal of choice and multiplied to millions of cells. The cells then differentiated into meat cells with a taste and texture that is comparable to traditional meat. Growth factors are essential for this process as they control the proliferation and differentiation of stem cells.

It has been estimated that 10 thousand kilos of meat could be produced from a single cattle stem cell and that stem cells from as few as 150 cattle could provide enough meat to supply the worlds current annual meat consumption. Similarly, stem cells from single cattle could provide enough meat to make 175 million hamburgers, of which 440 thousand cattle would otherwise have to be slaughtered.

ORF Genetics newest product, MESOkine, brings together ORF Genetics experience and expertise in barley biotechnology to produce affordable, easily scalable, high-qualitygrowthfactors essential to the CCM industry.

MESOkine is a defined barley seed extract, containing the purified recombinant growth factor along with selected barley seed proteins. The MESOkine portfolio will offer recombinant animal growth factors of the highest quality from different species. The first animal versions of MESOkine growth factors are in their final stages of development and will be available for testing in the summer of 2021.

MESOkine, which is plant-based, has important merits over animal growth factors. Its production bypasses entirely the use of bacteria and the use of animal or human cells, resulting in endotoxin-free growth factors. Endotoxin is a lipopolysaccharide (LPS) in the outer membrane of gram-negative bacteria like E. coli, where it serves as a major structural component.

Since E. coli-based production systems are the most used expression systems for recombinant proteins, endotoxin contamination has long been a considerable problem for researchers and manufacturers. Therefore, applying endotoxin-free growth factors leads to increased precision, increased reproducibility, time and resource efficiency, and a smoother transfer of pre-clinical experiments to clinical trials.

Environmental and ethical concerns regarding the conventional meat industry have resulted in increasing numbers of people choosing to decrease their meat consumption, a trend that is pushing forward CCM development. The global consulting firm Kearney has projected that CCM will have gained a 10% share of the global meat market by 2030, increasing to 35% by 2040.

The first steps of CCM to market have already been taken. In December 2020, Singapore gave regulatory approval for chicken meat produced by the U.S. start-up Eat Just. Since then, Eat Justs chicken nuggets have already been served at a restaurant in Singapore, making them the worlds first commercial sale of CCM. Singapores regulatory approval is an important milestone for the CCM industry, as its success is heavily dependent on regulatory approval across the world.

Several entrepreneurs report they are soon ready for scale-up and market launch. For instance, the Dutch entrepreneur Mosa Meat is working on pilot plant production of CCM hamburgers and scaling down costs, and the French start-up Gourmey aims to market its cell cultured foie gras by 2023 or 2024.

It is no longer a question of if, but rather when CCM reaches supermarket shelves across the world. CCM production is still relatively expensive compared to conventional meat, and reducing costs is, therefore, key to getting CCM to market on a larger scale.

ORF Genetics aims for a paradigm shift in cell cultured meat production with its new product line by meeting the industrys needs for dramatic cost reduction and access tofast scale-up for animal growth factors. MESOkines unique qualities will aid in cost reduction and up-scaling of CCM production, with safer and more precise growth factors than currently available.

*Please note: This is a commercial profile

Editor's Recommended Articles

Go here to see the original:

Cell Culture: Disrupting the Meat Industry - Open Access Government

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *